PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PTC Therapeutics reports robust earnings, faces data release delays

PTC Therapeutics demonstrated strong financial performance and revenue growth in Q4 2022, setting a positive trajectory for 2023.
While facing challenges such as data release delays and regulatory engagements, the company's innovative pipeline and commercial successes position it well for future opportunities.
With upcoming data readouts, regulatory discussions, and market expansion initiatives, PTC is poised to navigate challenges and leverage opportunities for continued growth and impact.

PTC Therapeutics achieves record revenue, faces regulatory challenges and growth opportunities

PTC Therapeutics reported strong financial performance in Q1 2023, with a clear path towards achieving revenue targets. While facing challenges such as regulatory interactions and data expectations, the company is leveraging opportunities in upcoming study results and strategic initiatives to drive growth and market differentiation.

PTC Therapeutics reports strong Q2 revenue and advances pipeline

PTC Therapeutics showcased robust financial performance, positive trial outcomes, and strategic cost-saving measures in Q2 2023.
The company's strong revenue growth, global expansion plans, and pipeline advancements position it for sustained success.
Challenges include addressing analyst inquiries, navigating regulatory pathways, and ensuring market access post-2024.
Opportunities in product launches, regulatory activities, and strategic partnerships offer avenues for continued growth and innovation.

PTC Therapeutics reports robust Q3 earnings and strategic growth plans

PTC Therapeutics demonstrated strong financial performance and strategic partnerships in Q3 2023 earnings call.
The company's focus on pipeline advancement, commercial growth, and regulatory strategies positions it for future success.
While facing challenges in regulatory compliance and product comparability, PTC Therapeutics is leveraging opportunities for revenue growth and market expansion.

PTC Therapeutics posts robust Q4 earnings amidst regulatory challenges

PTC Therapeutics delivered strong financial performance in Q4 2023, driven by revenue growth and transformative gene therapy results, despite challenges from the CHMP opinion.
The company's strengths lie in its solid balance sheet, positive community feedback, and FDA alignment on registration programs, positioning it for future growth and approvals.
Opportunities abound in the launch of sepiapterin, accelerated approval discussions with the FDA, and promising programs for FA and ALS, signaling a positive outlook for PTC.

PTC Therapeutics reports robust Q1 performance amidst regulatory milestones

PTC Therapeutics demonstrated strong financial and operational performance in Q1 2024, driven by revenue growth and regulatory progress.
While facing challenges such as delays in European market access and regulatory complexities, the company remains focused on key therapeutic advancements.
Opportunities lie in upcoming clinical results, potential market expansions, and strategic regulatory pathways for accelerated product approvals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

- 2023 Program to Focus on Innovation and Transition to Adulthood Initiatives – - Submissions Due March 17, 2023 - SOUTH PLAINFIELD, N.J. , Jan. 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the ninth annual STRIVE™ awards program.

PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

PTC Therapeutics (PTCT) Soars 5.8%: Is Further Upside Left in the Stock?

-  ~$710 million unaudited 2022 total revenue, representing an impressive over 30% year-over-year growth – -  $940 million - $1.0 billion 2023 total revenue guidance – -  Results from three registration-directed clinical trials expected in 2023 – -  One additional registration-directed clinical trial expected to initiate in 2023 – SOUTH PLAINFIELD, N.J. , Jan. 9, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 41st Annual J.P.

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference

Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2023) - Kaskela Law LLC announces that it is investigating PTC Therapeutics, Inc. (NASDAQ: PTCT) on behalf of the company's long-term investors.The investigation seeks to determine whether PTC has issued false and misleading statements and/or failed to disclose material facts to its investors, thereby violating the securities laws and causing harm to the company's shareholders.PTC shareholders are encouraged to contact Kaskela Law LLC (Adrienne Bell, Esq.

Kaskela Law LLC Announces Investigation of PTC Therapeutics, Inc. (PTCT) and Encourages Long-Term PTCT Investors to Contact the Firm

SOUTH PLAINFIELD, N.J. , Jan. 4, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41st Annual J.P.

PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference

New York, New York--(Newsfile Corp. - December 5, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of PTC Therapeutics, Inc. (NASDAQ: PTCT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you own PTCT please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245.

Moore Kuehn, PLLC Encourages Investors of PTC Therapeutics, Inc. to Contact Law Firm

Coupa Software

Hive Blockchain Technologies Ltd

Lyft

Marathon Digital Holdings

Opendoor

Zillow

While the concept of Nasdaq stocks to sell won't resonate too kindly with generally optimistic Americans, it's become a reality. It's not just about the fact that on a year-to-date basis, the benchmark S&P 500 index still trades in negative territory.

7 Nasdaq Stocks to Sell Before They Plunge in 2023

- First global regulatory approval for treatment of this rare genetic disease - SOUTH PLAINFIELD, N.J. , Dec. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra™ (volanesorsen) as the first treatment for familial partial lipodystrophy (FPL) in Brazil.

Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy

- Upstaza™ is the first gene therapy infused directly into the brain for the treatment of AADC deficiency - - MHRA authorization follows recent European Union authorization - - AADC deficiency is a rare, fatal disorder that arrests motor development causing severe disability - SOUTH PLAINFIELD, N.J. , Nov. 17, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec) was granted authorization by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain.

Upstaza™ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA

Altra Industrial Motion

Carvana

Generac Holdings

Maravai LifeSciences Holdings

Norwegian Cruise Line

Olaplex Holdings

Vaxcyte

Patterson-UTI Energy

Mid-cap companies lie in between the slower growth large-cap stocks and the faster-growth small-cap businesses.

These Were The Five Best And Worst Performing Mid-Cap Stocks In October 2022

The registration-directed phenylketonuria study results are anticipated by the end of the quarter. Management claims there are about 58,000 PKU patients globally that they can target by 2030.

PTC Therapeutics: PKU Trial News Likely To Shore Up Share Price

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why PTC Therapeutics (PTCT) is Poised for a Turnaround After Losing 23.4% in 4 Weeks

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2022 Results Conference Call October 27, 2022 4:30 PM ET Company Participants Kylie O'Keefe - SVP, Head of Global Commercial and Corporate Strategy Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Operating Officer Eric Pauwels - Chief Business Officer Emily Hill - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph - JPMorgan Joseph Thome - Cowen Alexander Xenakis - Truist Raju Prasad - William Blair Gena Wang - Barclays Danielle Brill - Raymond James Kelly Shi - Jefferies Judah Frommer - Credit Suisse Tazeen Ahmad - Bank of America Operator Hello. Thank you for standing by.

PTC Therapeutics, Inc. (PTCT) Q3 2022 Earnings Call Transcript

- Total quarterly revenue of $217 million, representing 57% year-over-year growth - - 2022 DMD revenue guidance and low end of total revenue guidance increased - - Strategic financing with Blackstone with up to $1 billion of low-cost, low-dilution capital - - Pipeline of multiple innovative compounds continues to advance in clinical development - SOUTH PLAINFIELD, N.J. , Oct. 27, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2022.

PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results 

Blackstone Group

- Blackstone investment accelerates innovative product pipeline - - PTC will leverage Blackstone's network and life sciences expertise to broaden business development effort - - PTC to receive $350 million in cash at close - SOUTH PLAINFIELD, N.J. and NEW YORK , Oct. 27, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into a strategic financing collaboration with funds managed by Blackstone (NYSE: BX) to support its mission to reach a steady-state of delivering at least one therapy every 2-3 years to continue to bring transformative medicines to patients globally.

PTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

The FDA requests additional data to allow PTC Therapeutics (PTCT) to continue enrollment in its phase II PIVOT-HD study evaluating PTC518 for treating Huntington's disease in the United States. Stock down.

PTC Therapeutics (PTCT) Halts Huntington's Disease Study in US

Shares of PTC Therapeutics Inc. PTCT, -10.87% were down 10.1% in trading on Wednesday morning, the day after the company said enrollment in a Phase 2 clinical trial for its Huntington's disease treatment candidate has been paused. PTC told investors on Tuesday night that the Food and Drug Administration had requested additional information about the study.

PTC Therapeutics shares fall 10% after announcing pause in U.S. enrollment for a clinical trial

SOUTH PLAINFIELD, N.J. , Oct. 18, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) confirmed today that enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the treatment of Huntington's disease at study sites globally.

PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518

SOUTH PLAINFIELD, N.J. , Oct. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2022 financial results and provide an update on the company's business and outlook on Thursday, Oct. 27, at 4:30 p.m.

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2022 Financial Results

- Presentations include age of loss of ambulation and preservation of upper limb function following treatment with Translarna in patients with nonsense mutation Duchenne muscular dystrophy - SOUTH PLAINFIELD, N.J. , Oct. 11, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that recent clinical trial and real-world evidence on the efficacy and safety of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) will be presented at the 27th International Annual Congress of the World Muscle Society (WMS) in Halifax, Nova Scotia, Canada.

PTC Therapeutics to Present Clinical and Real-World Evidence on Translarna™ at the Annual Congress of the World Muscle Society

NEW YORK--(BUSINESS WIRE)---- $PTCT #NYTop100--Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of PTC Therapeutics (NASDAQ: PTCT) (“PTC” or the “Company”). The investigations concern whether certain of the Company's officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of P

Newman Ferrara LLP Announces Corporate Governance Investigations of PTC Therapeutics (PTCT)

- 2022  recipients include patient advocacy organizations from Brazil, Greece, Turkey, and the U.K. - SOUTH PLAINFIELD, N.J. , Sept. 7, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the four recipients of its 2022 STRIVE Awards for Duchenne Muscular Dystrophy.

PTC Therapeutics' 2022 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community

NEW YORK , Aug. 18, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of PTC Therapeutics, Inc. (NASDAQ: PTCT). If you are a shareholder of PTC Therapeutics, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/ptc-therapeutics-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating PTC Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Apellis Pharma

Beam Therapeutics

Chemocentryx

Fate Therapeutics

Global Blood Therapeutics

Karuna Therapeutics Inc

Intellia Therapeutics

Repligen

Twist Bioscience Corp

Barron's screened for stocks such as Global Blood Therapeutics and Karuna Therapeutics that popped this summer.

News for PTC Therapeutics Stock (PTCT)